Justin Zelin, an analyst from BTIG, reiterated the Buy rating on Mersana Therapeutics (MRSN – Research Report). The associated price ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback